Zydus Cadila informed the exchanges on Wednesday that it has received tentative approval from United States Food & Drug Administration (USFDA) to market Empagliflozin and Linagliptin tablets (US RLD: Glyxambi tablets) in the strengths of 10 mg/5 mg and 25 mg/5 mg.

During Wednesday’s trading session, gold prices slipped again as profit booking was seen across equities. Sensex was in negative territory, down by more than 300 points.

Lately, we have seen people moving from mutual funds to investing in direct stocks. Here are a few things that one should remember while making such a switch.

This is for the second time that Silver Lake has shown interest in investing in the subsidiary of Reliance Industries after the $1.35 billion investment in Jio Platforms, earlier this year.

On the other side, the global automotive industry's outlook has been changed to stable from negative. It said that the stable outlook for the global automotive industry reveals growing sales through 2021, with continued but slow increase through 2023.

The consolidated net sales reported in Q1FY21 came in at Rs 474.41 crore, which declined by 9.1 per cent YoY from Rs 521.9 crore in Q1FY20.

Fitch Ratings in its latest report has sharply lowered its forecast for India's gross domestic product (GDP) growth for the current fiscal year (FY21) to -10.5 per cent from -5 per cent estimated earlier

On Wednesday, the stock of AstraZeneca Pharma India tumbled by more than 11 per cent on BSE. The company’s parent company AstraZeneca PLC issued a statement stating that the standard review process has triggered a pause to the clinical trial of its COVID-19 vaccination to allow the review of safety data.

Dr Reddy’s Laboratories Ltd announced the launch of Remdesivir along with its subsidiaries on Wednesday. The product is being launched under the brand name of Redyx in India. Additionally, it also announced the launch of over-the-counter (OTC) Diclofenac Sodium Topical Gel 1 per cent, the store brand version of Voltaren® Arthritis Pain in the US market.

The company will be conducting its 36^th annual general meeting (AGM) on September 29, 2020. The stock has generated returns of 29 per cent on an annualised basis in the past 10 years. However, since the last three years, the stock has underperformed heavily, generating negative of 15.30 per cent on an annualised basis.